40.45Open40.45Pre Close0 Volume7 Open Interest200.00Strike Price0.00Turnover52.56%IV-1.81%PremiumDec 20, 2024Expiry Date44.89Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9373Delta0.0036Gamma5.27Leverage Ratio-0.1022Theta0.1310Rho4.94Eff Leverage0.0807Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet